International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7912885
Original Article
Non-Pneumatic Anti Shock Garment (NASG) in Post Partum Haemorrhage-Our Experience
 ,
 ,
 ,
Published
April 30, 2023
Abstract
Introduction: Non-pneumatic Anti-Shock Garment (NASG) is a unique, Life -saving, first -aid device made of neoprene and Velcro, which is used on women with obstetric haemorrhage. The NASG has a unique role in haemorrhage and shock management because, it is meant to be used with, not instead of, other technologies. Currently, it is the only tool that aids in stabilizing pulse and blood pressure after a woman has gone into shock from obstetric haemorrhage. Aims And Objectives: To study sociodemographic profile, stage of shock, different types of Post Partum Haemorrhage, safety, and efficacy of Non pneumatic Anti Shock Garment. Methodology: A Prospective observational study was conducted in department of Obstetrics and Gynaecology in Government medical college, Aurangabad, Maharashtra. Detail history, demographics characteristics, aetiology or risk factors, maternal complication were recorded and analysed. Primary data was collected in paper based proforma and the data was then entered in Microsoft Excel spreadsheets. Statistical analysis was done tests. Results: The mean age of the woman was 24.32. 44% women were from urban area and 56%were from rural area. 29(58%) women were having secondary education. Around 74% women belonged to lower middle class. 52% women were unbooked and 48%were booked cases. The women unemployed were accounting for 56%. 68% were multipara with Abruptio placenta being the most common risk factor in 18%. Atonicity was seen in 62%women of PPH, and majority of the women were applied NASG in stage 2 (54%). There was significant improvement in the pulse rate, Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Pressure after application of NASG and hence proved to be efficacious. Only 1woman had died with PPH being the immediate cause of death. NASG was applied in 94% women for 12-24 hrs. The shock index improved drastically after NASG application. Moreover, NASG use was not associated with any side effects and hence was considered safe. Conclusion: The use of NASG as an adjunct to main treatment was found to be very efficacious in reversing life-threatening haemorrhagic shock, and is found to be a cost effective, reusable and a viable tool with no major side effects and discomfort in reducing the maternal mortality in all cases of PPH.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1178 Views
377 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved